People — Neely Lab

Team Leader Associate Professor Greg Neely

I completed my PhD in human immunology at the University of Calgary, Canada and went on to train in functional genomics with Josef Penninger in Vienna, Austria. Since 2011 I have been running a lab in Sydney Australia using functional genomics approaches to find novel human disease genes and pathways. My main interest is in age-related diseases involving the nervous system, including pain, neurodegeneration, and strategies to extend lifespan while preserving overall health.

The Team

Dr Willie Lin - Senior Research Fellow

Sumire Antonioli- Research Technician

Dr Jenny Cao - Research Assistant

Leslie%20NC.jpg

Dr Leslie Caron - Senior Research Associate and Chong Fellow

Brandon Carr - Student

Teleri Clark - Research Assistant

Tiffany Cole - PhD Student

Elizabeth Ford - Student

Zina Hamoudi - Research Assistant

Dr Thang Khuong - Postdoctoral Research Associate

Dylan Kilpatrick-Volunteer

Marco Donato Lamonaca - Research Technician

Dr Raymond Lau - Postdoctoral Research Associate

Jaimie B. Littleboy - Research Assistant

John Manion - PhD Student

Lisa Oyston - PhD Student

Jodie Pearlman - Student

Dr Kevin Wang - Postdoctoral Research Associate

Neely Lab

Our lab is focused on the systematic functional annotation of the genome. The long-term objective of our research is to identify genes and coding mutations that participate in major age-related and neurological diseases. Our overall research strategy is to combine human population genomics (GWAS or sequencing) data with high throughput functional validation in fruit flies and mammalian systems to identify new genes that contribute to human disease.

We have developed novel functional genomics strategies that we use to identify genes involved in various normal or disease states. Currently we have projects that relate to heart function, pain perception, neurodegeneration, lifespan and metabolic disorders, kidney function, and cancer. In the end our goal is to rapidly improve patient treatment, and many of the new genes we have identified appear to be viable drug targets.